PX
56
3
CLX
65
2
MET
58
2
ES
12
3
MMM
35
3
UNH
42
6
ADI
54
4
AES
47
4
PWR
63
3
EXPD
29
2
JWN
72
9
MDLZ
28
2
DHI
36
3
SIG
52
5
LMT
29
-5
MSI
52
3
AEP
45
5
KLAC
45
3
SCHW
40
3
ILMN
31
4
PX
56
3
CLX
65
2
MET
58
2
ES
12
3
MMM
35
3
UNH
42
6
ADI
54
4
AES
47
4
PWR
63
3
EXPD
29
2
JWN
72
9
MDLZ
28
2
DHI
36
3
SIG
52
5
LMT
29
-5
MSI
52
3
AEP
45
5
KLAC
45
3
SCHW
40
3
ILMN
31
4
Financhill
Back

Nektar Therapeutics 10K Form

Sell
25

NKTR
Nektar Therapeutics

Last Price:
$0.89
Seasonality Move:
6.78%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-10 10Q NKTR/Nektar Therapeutics Quarterly
2023-11-08 10Q NKTR/Nektar Therapeutics Quarterly
2023-08-09 10Q NKTR/Nektar Therapeutics Quarterly
2023-05-10 10Q NKTR/Nektar Therapeutics Quarterly
2022-11-04 10Q NKTR/Nektar Therapeutics Quarterly
2022-08-05 10Q NKTR/Nektar Therapeutics Quarterly

Receive NKTR News And Ratings

See the #1 stock for the next 7 days that we like better than NKTR

NKTR Financial Statistics

Sales & Book Value

Annual Sales: $90.1M
Cash Flow: $-44.6M
Price / Cash Flow: 0
Annual Sales: $0.27
Price / Book: 3.5

Profitability

EPS (TTM): -0.84000
Net Income (TTM): $-168.3M
Gross Margin: $56.4M
Return on Equity: -154.23%
Return on Assets: -44.58%

Nektar Therapeutics Earnings Forecast

Key Nektar Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 30 years for NKTR is 62.53%.
  • The Selling, General & Administrative Expenses for NKTR have been equal to 85.90% of Gross Profit Margin.
  • The Research & Development expenses have been 126.67% of Revenue.
  • The Interest Expense is -9.18% of Operating Income.
  • The Net Earning history of NKTR is -306.31% of Total Revenues.
  • Per Share Earnings over the last 30 years have been positive in 14 years.

Nektar Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: NKTR
CUSIP: 640268
Website: nektar.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.24
Quick Ratio: 3.65

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

NKTR Technical Analysis vs Fundamental Analysis

Sell
25
Nektar Therapeutics (NKTR) is a Sell

Is Nektar Therapeutics a Buy or a Sell?